Traditional Chinese medicine decoction for treating myeloproliferative disorder syndrome

Abstract

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine decoction for treating a myeloproliferative disorder syndrome. The traditional Chinese medicine decoction is prepared from the following traditional Chinese medicine raw materials by weight percentage: 6-9% of Japanese polygala, 7-10% of cornu bubali, 6-9% of fructus polygoni orientalis, 8-10% of herba rabdosiae, 6-8% of plantain herb, 2-5% of vervain, 5-8% of lalang grass rhizome, 3-5% of prismatomeris tetrandra, 2-4% of lignum dalbergiae odoriferae, 2-5% of herba orostachyos, 3-6% of rhizoma smilacis glabrae, 2-4% of kelp, 2-4% of changium smyrnioides, 2-5% of bunge corydalis herb, 2-4% of fructus gardeniae praeparatus, 1-3% of oviductus ranae, 1-3% of folium artemisiae argyi, 1-3% of agilawood, 2-4% of fructus aurantii immaturus, 4-7% of poria, 2-5% of purslane and 2-4% of pyrrosia lingua. The decoction has a high curative effect on treating the myeloproliferative disorder syndrome, is free of toxic or side effect, and has the effects of clearing away heat and toxic materials, cooling blood, enriching the blood, promoting the circulation of qi, restoring a menstrual flow, stop bleeding by astringency, supporting yang, dissolving phlegm, resolving a hard lump, promoting blood circulation, diminishing swelling, alleviating pain, nourishing yin, tonifying a kidney, filling marrow, strengthening a spleen, nourishing the blood, preventing a cancer and the like, completely suppresses a malignant abnormal clone hyperplasia myeloid tissue, thoroughly restores immunodeficiency of an organism, improves resistance and has a total effective rate of 85.9%.

Description

technical field [0001] The invention relates to a Chinese herbal medicine preparation, in particular to a Chinese medicine decoction for treating myelodysplastic syndrome. Background technique [0002] Myelodysplastic syndromes are a group of heterogeneous diseases originating from hematopoietic stem cells, characterized by pathological hematopoiesis, high risk of transformation to acute leukemia, and manifested as refractory blood diseases with one or more lineage cytopenias. Men and women of any age can be affected, and about 50% of patients are older than sixty years old. The etiology of the disease is still unclear, and secondary myelodysplastic syndrome is seen in close contacts of alkylating agents, radiation, and organic poisons. Through restriction fragment length polymorphism analysis and other clonal analysis techniques, it is found that myelodysplastic syndrome is a clonal disease originating from hematopoietic stem cells. Abnormal clonal cells differentiate in t...

AI Technical Summary

Problems solved by technology

However, because the disease is an elderly patient, the mortality rate of transplantation is relatively high, there is no suitable bone marrow matching, and the family's economic conditions are poor, which are recognized difficulties in the medical field